RICHARD STEVEN BLUMBERG, MD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 50768
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
75 Brigham And Womens Hospital Gastroenterology Division, Boston, MA 02115
Phone
(617) 732-5500
(617) 732-5824
(617) 732-5824
Personal information
See more information about RICHARD STEVEN BLUMBERG at radaris.comName
Address
Phone
34 Lagrange St, Chestnut Hill, MA 02467
12 Bowker St, Lexington, MA 02421
195 Fox Rd UNIT 101, Waltham, MA 02451
24 La Grange Pl, Chestnut Hill, MA 02467
34 La Grange Pl, Chestnut Hill, MA 02467
Professional information
Richard Steven Blumberg, Boston MA
Specialties:
Gastroenterologist
Address:
75 Francis St, Boston, MA 02115
Education:
Thomas Jefferson University, Jefferson Medical College - Doctor of Medicine
Brigham & Women's Hospital - Fellowship - Gastroenterology (Internal Medicine)
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Family Medicine
Brigham & Women's Hospital - Fellowship - Gastroenterology (Internal Medicine)
New York Presbyterian Hospital/Weill Cornell Medical Center - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Richard Steven Blumberg, Boston MA
Specialties:
Internal Medicine, Gastroenterology, Infectious Disease
Work:
Dana-Farber Cancer Institute
75 Francis St, Boston, MA 02115
75 Francis St, Boston, MA 02115
Education:
Thomas Jefferson University (1979)
Receptor Specific Transepithelial Transport Of Therapeutics
US Patent:
6485726, Nov 26, 2002
Filed:
Jul 24, 1998
Appl. No.:
09/122144
Inventors:
Richard S. Blumberg - Chestnut Hill MA
Neil E. Simister - Wellesley MA
Wayne I. Lencer - Jamaica Plain MA
Neil E. Simister - Wellesley MA
Wayne I. Lencer - Jamaica Plain MA
Assignee:
The Brigham and Womens Hospital, Inc. - Boston MA
Brandeis University - Waltham MA
Brandeis University - Waltham MA
International Classification:
A61K 3900
US Classification:
4241781, 4241851, 4241921, 4241931, 4242771
Abstract:
The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.
Use Of Resolvins To Treat Gastrointestinal Diseases
US Patent:
2006029, Dec 28, 2006
Filed:
Jan 5, 2006
Appl. No.:
11/326134
Inventors:
Charles Serhan - Needham MA, US
Makoto Arita - Brookline MA, US
Masaru Yoshida - Newton MA, US
Richard Blumberg - Chestnut Hill MA, US
Makoto Arita - Brookline MA, US
Masaru Yoshida - Newton MA, US
Richard Blumberg - Chestnut Hill MA, US
International Classification:
A61K 31/655, A61K 31/5375, A61K 31/551, A61K 31/496, A61K 31/445, A61K 31/277, A61K 31/275, A61K 31/20, A61K 31/18, A61K 31/16, A61K 31/10
US Classification:
514149000, 514218000, 514231200, 514317000, 514252120, 514560000, 514150000, 514519000, 514601000, 514625000, 514740000, 514514000, 514708000, 514640000
Abstract:
The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA and DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate gastrointestinal conditions, for example, such as colitis. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
Receptor Specific Transepithelial Transport Of Therapeutics
US Patent:
6030613, Feb 29, 2000
Filed:
Jul 24, 1997
Appl. No.:
8/899856
Inventors:
Richard S. Blumberg - Chestnut Hill MA
Neil E. Simister - Wellesley MA
Wayne I. Lencer - Jamaica Plain MA
Neil E. Simister - Wellesley MA
Wayne I. Lencer - Jamaica Plain MA
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
Brandeis University - Waltham MA
Brandeis University - Waltham MA
International Classification:
A61K 39385, A61K 3944
US Classification:
4241341
Abstract:
The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.
Central Airway Administration For Systemic Delivery Of Therapeutics
US Patent:
2006014, Jun 29, 2006
Filed:
Jan 20, 2006
Appl. No.:
11/336581
Inventors:
Richard Blumberg - Chestnut Hill MA, US
Wayne Lencer - Jamaica Plain MA, US
Neil Simister - Wellesley MA, US
Alan Bitonti - Acton MA, US
Wayne Lencer - Jamaica Plain MA, US
Neil Simister - Wellesley MA, US
Alan Bitonti - Acton MA, US
International Classification:
A61K 38/21, A61K 38/18, A61K 38/37, A61K 48/00
US Classification:
424085600, 424085700, 514012000, 514044000
Abstract:
The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.
Receptor Specific Transepithelial Transport Of Immunogens
US Patent:
6086875, Jul 11, 2000
Filed:
Jan 17, 1995
Appl. No.:
8/374159
Inventors:
Richard S. Blumberg - Chestnut Hill MA
Neil E. Simister - Wellesley MA
Wayne L. Lencer - Jamaica Plain MA
Neil E. Simister - Wellesley MA
Wayne L. Lencer - Jamaica Plain MA
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
Brandeis University - Waltham MA
Brandeis University - Waltham MA
International Classification:
A61K 39385, A61K 3944
US Classification:
4241341
Abstract:
Methods and products for modulating an immune response are provided. Pharmaceutical preparations contain a conjugate of an antigen and a FcRn binding partner. The conjugates are administered to mammals in effective amounts to modulate the immune system by stimulating the immune response against the antigen or tolerizing the immune system to the antigen. The antigen may be characteristic of a pathogen, of an autoimmune disease or of an allergen.
Methods Of Treating And Preventing Colitis Involving Il-13 And Nk-T Cells
US Patent:
7666411, Feb 23, 2010
Filed:
Jun 14, 2002
Appl. No.:
10/517898
Inventors:
Warren Strober - Bethesda MD, US
Ivan J. Fuss - Bethesda MD, US
Frank Heller - Berlin, DE
Richard S. Blumberg - Chestnut Hill MA, US
Ivan J. Fuss - Bethesda MD, US
Frank Heller - Berlin, DE
Richard S. Blumberg - Chestnut Hill MA, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
The Brigham & Women's Hospital, Inc. - Boston MA
The Brigham & Women's Hospital, Inc. - Boston MA
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. ). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
T Cell Inhibitory Receptor Compositions And Uses Thereof
US Patent:
6852320, Feb 8, 2005
Filed:
Jun 19, 2001
Appl. No.:
09/884196
Inventors:
Richard S. Blumberg - Chestnut Hill MA, US
Assignee:
The Brigham & Women's Hospital, Inc. - Boston MA
International Classification:
A61K039/395, A61K038/16, C07K016/28
US Classification:
4241331, 4241341, 4241541, 514 8, 5303871, 5303873, 5303882, 53038873, 53038885, 530395
Abstract:
The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided.
Methods Of Inhibiting Inflammation
US Patent:
2005023, Oct 20, 2005
Filed:
Feb 9, 2005
Appl. No.:
11/054931
Inventors:
Richard Blumberg - Chestnut Hill MA, US
International Classification:
A61K031/506, A61K031/4545, A61K031/454, A61K031/427, A61K031/422, A61K031/4184
US Classification:
514256000, 514319000, 514318000, 514326000, 514365000, 514374000, 514384000
Abstract:
The invention provides a method of inhibiting inflammation in a mammal, by administering to the mammal composition containing a compound which inhibits the expression or activity of a microsomal triglyceride transfer protein.